ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2630

Complement C4d Split Products in Combination with Lupus Anticoagulant and Low Complement Associate with Thrombosis in Systemic Lupus Erythematosus

Michelle Petri1, John Conklin2, Robert Apilado2, Tyler O'Malley2, JoAnne Ligayon2, Leilani Wolover2 and Thierry Dervieux2, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2Exagen Diagnostics, Inc., Vista, CA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Anticoagulation, Clinical research, complement and thrombosis, SLE

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Systemic Lupus Erythematosus – Clinical Poster III: Treatment

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Lupus anticoagulant (LAC) is an established risk factor for thrombosis in systemic Lupus erythematosus (SLE). Emerging data suggest that activation of the complement system is also involved in the pathogenesis of thrombosis. Our objective was to evaluate the relationships between complement C4d split products deposited on erythrocytes (EC4d), Platelets (PC4d) and thrombosis in SLE.
Methods: This was a cross sectional analysis of 148 consented SLE patients (by ACR or SLICC criteria; 82% ANA positive [>1:80] by indirect immunofluorescence; mean age: 47±1 years, 32% taking prednisone; mean SELENA-SLEDAI: 2.5±0.2 points). SLE were classified with (n=16, 11%) or without (n=132, 89%) a history of thrombotic events (venous or arterial) in the past 5 years. EC4d and PC4d levels were measured using quantitative flow cytometry, and expressed as mean fluorescence intensity (MFI) (abnormal EC4d>14 net MFI, PC4d>20 net MFI, each corresponding to the 99th percentile of normal healthy group). Complement C3, C4 and LAC were measured using immunochemistry (low C3<81 mg/dl, low C4<12.9 mg/dl) and Dilute Russell Viper Venom Time (positive DRVVT>37 seconds), respectively. Statistical analysis consisted of Mann Whitney test and logistic regression.
Results: SLE with a history of thrombosis in the past 5 years presented with 5.5 and 2.2-fold higher median PC4d (27 [IQR: 8-79 net MFI] vs 5 [IQR: 2-14 net MFI] net MFI) and EC4d (19 [IQR: 9-59 net MFI] vs 9 [IQR: 6-19] net MFI]) levels, respectively, than SLE without thrombotic events (p<0.001; n=148). Low C3 (OR=10.5 [CI 95%: 2.6-42.0]), low C4 (OR=3.5 [CI 95%: 1.1-11.1), abnormal PC4d (OR=19.0 [CI 95%: 3.7-96.4; n=148), EC4d (OR=4.0 [CI95%: 1.3-11.8]), and LAC (OR=5.3 [CI 95%: 1.1-24.5; n=144) were all significantly associated with thrombosis (p<0.035). Prednisone was also associated with thrombosis (OR=3.2 [CI95%: 1.1-8.9]) (p=0.037). Multivariate analysis revealed that low C3, abnormal PC4d and LAC were all independently and significantly associated with thrombosis (p<0.027) and the cumulative presence of these abnormalities resulted in higher likelihood of thrombosis (OR range: 81.9 CI95%: 9.7-688.5; n=144) (p<0.001) (Figure). These results remained significant after adjusting for prednisone.
Conclusion: Complement C4d split products associate with thrombotic events in SLE, independent of other risk factors. A composite score of risk factors performed better than single risk factors alone, and should be studied prospectively.


Disclosure: M. Petri, Exagen Diagnostics, Inc., 2; J. Conklin, Exagen Diagnostics Inc., 3; R. Apilado, Exagen Diagnostics, 3; T. O'Malley, Exagen Diagnostics, 3; J. Ligayon, Exagen Diagnostics, Inc, 3; L. Wolover, Exagen Diagnostics, Inc., 3; T. Dervieux, exagen, 3.

To cite this abstract in AMA style:

Petri M, Conklin J, Apilado R, O'Malley T, Ligayon J, Wolover L, Dervieux T. Complement C4d Split Products in Combination with Lupus Anticoagulant and Low Complement Associate with Thrombosis in Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/complement-c4d-split-products-in-combination-with-lupus-anticoagulant-and-low-complement-associate-with-thrombosis-in-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/complement-c4d-split-products-in-combination-with-lupus-anticoagulant-and-low-complement-associate-with-thrombosis-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology